Association of melanoma with intraepithelial neoplasia of the pancreas in three patients by Fidalgo, Felipe et al.
  Universidade de São Paulo
 
2014-08
 
Association of melanoma with intraepithelial
neoplasia of the pancreas in three patients
 
 
Experimental and Molecular Pathology, Maryland Heights, v.97, n.1, p.144-147, 2014
http://www.producao.usp.br/handle/BDPI/45851
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Genética e Biologia Evolutiva - IB/BIO Artigos e Materiais de Revistas Científicas - IB/BIO
Association ofmelanomawith intraepithelial neoplasia of the pancreas in
three patients
Felipe Fidalgo a, Elimar Elias Gomes b, LucianaMoredo Facure b, Felipe Carneiro Da Silva a, DirceMaria Carraro a,
Bianca Costa Soares de Sá b, João Pedreira Duprat Neto b, Ana Cristina Victorino Krepischi a,c,⁎
a International Research Center, AC Camargo Cancer Center, São Paulo, Brazil
b Department of Skin Cancer, AC Camargo Cancer Center, São Paulo, Brazil
c Department of Genetics and Evolutionary Biology, University of São Paulo, Brazil
a b s t r a c ta r t i c l e i n f o
Article history:
Received 11 June 2014
Available online 28 June 2014
Keywords:
Germline copy number variation
CNV
Melanoma
Pancreatic cancer
Intraepithelial neoplasia of pancreas
Melanoma and pancreatic cancer are two low frequency types of cancer. In this study, three patients who devel-
oped both melanoma and intraepithelial neoplasia of the pancreas were tested for CDKN2Amutations and dele-
tions, and investigated for rare germline copy number variations (CNVs). The three patients were negative for
CDKN2A point mutations and intragenic deletions. One of these patients carried two large (N300 kb) germline
CNVs, both genomic duplications affecting coding sequences that are not copy number variable in the population.
A second patient exhibited loss of the entire Y chromosome, an event probably coincidental related to his ad-
vanced age (79 years-old). Our data pinpoint that rare germline CNVs harboring genes can contribute to the can-
cer predisposition of melanoma and intraepithelial neoplasia of the pancreas.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).
Introduction
Pancreatic cancer has oneof thehighest death rates among all cancer
types. The relative 5-year survival rate of pancreatic cancer in the USA
was estimated in 6% (http://seer.cancer.gov/), primarily due to the late
detection of the disease and the lack of effective treatment (Ma and
Jemal, 2013).
It is already known that familial history of pancreatic cancer is
an important risk factor associated with this tumor development
(Permuth-Wey and Egan, 2009). Nevertheless, only 20% of all familial
pancreatic cancer has a known genetic etiology. Mutations in some spe-
ciﬁc genes were already reported increasing the susceptibility to pan-
creatic cancer, such as BRCA1, BRCA2, ATM, STK11, PRSS1, and PALB2
(Jones et al., 2009; Solomon et al., 2012). In addition, some previous
studies have established that familial history of melanoma is a risk fac-
tor to the development of pancreatic cancer (Rustgi, 2014; Zavoral et al.,
2011). Melanoma exhibits a low but increasing incidence (Jemal et al.,
2006), and although accounting for only 4% of all skin cancer cases, mel-
anoma is responsible for approximately 75% of all deaths caused by cu-
taneous neoplasias (Schinke et al., 2010). Among all melanoma cases,
approximately 10% occur in a familial context, and up to 40% of the fa-
milial melanoma are caused by mutations affecting the CDKN2A gene,
mainly the p16 variant (Pho et al., 2006). CDKN2A mutation is
associated with the occurrence of pancreatic cancer in familial melano-
ma with a cumulative risk of up to 20% by age 75 (Rustgi, 2014). Few
geneswere associatedwith the concomitant development ofmelanoma
and pancreatic cancer in the same patient, mainly the aforementioned
CDKN2A, and also BRCA1 (Bartsch et al., 2010; Solomon et al., 2012).
There are three precursor lesions giving rise to pancreatic cancer
that includes pancreatic intraepithelial neoplasia (PanIN), intraductal
papillarymucinous neoplasms (IPMNs) andmucinous cystic neoplasms
(MCNs), each of them arising in association with distinct genetic alter-
ations (Macgregor-Das and Iacobuzio-Donahue, 2013).
Pancreatic intraepithelial neoplasia (PanIN) can be divided in three
grades based on their degree of morphologic atypia and mucin output.
The entire spectrum – PanIN-1, PanIN-2, PanIN-3 – represents a gradual
neoplastic progression and cumulative alterations on gene expression,
including somatic mutations on KRAS2, TP53, CDKN2A, and MADH4/
SMAD4/DPC4 (Biankin et al., 2003; Macgregor-Das and
Iacobuzio-Donahue, 2013; Maire et al., 2013). PanINs are the most fre-
quent pancreatic cancer precursor, even though it may arise from any
of the three precursor lesions described above (Macgregor-Das and
Iacobuzio-Donahue, 2013). In preinvasive IPMN, mutations in KRAS,
TP53, BRAF, and in the serine/threonine kinase STK11/LKB1 have been
reported (Sahin et al., 2003; Schönleben et al., 2007). Mutations in
KRAS and TP53 have been also noted in higher-grade lesions of MCNs.
Germline copy number variations (CNVs) are gains and losses of
large genomic segments composing with other variants the genetic
background of human populations (Redon et al., 2006; Sebat et al.,
2004). CNVs encompass approximately 15% of the human genome,
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andmainly affect a subset of genes involved in immunity, interaction to
environment and infection (Li and Olivier, 2013). This type of genomic
variants can modulate the phenotype and therefore contributes to the
genetic individuality (Li and Olivier, 2013). Although most of the CNVs
are not pathogenic, several were causally related to congenital diseases,
and some were already associated with susceptibility to cancer, includ-
ing melanoma and pancreatic cancer (Al-Sukhni et al., 2012; Gonçalves
et al., 2012; Krepischi et al., 2012a, 2012b; Krepischi-Santos et al., 2006;
Lucito et al., 2007; Shaw-Smith et al., 2006; Yang et al., 2012). Therefore,
rare germline CNVs can harbor genes composing the genetic suscepti-
bility to cancer. Genomic proﬁles of germline CNVs of three melanoma
patients who also developed intraepithelial neoplasia of the pancreas
were assessed in order to ﬁnd rare variants possibly related to the
phenotype.
Materials and methods
Study approval and patient samples
The patients were ascertained at the Skin Cancer Department of the
A. C. Camargo Cancer Center, São Paulo, Brazil (ACCCC). This is a retro-
spective study approved by the local Ethics and Research Committee
of the Institution (#1728/12), and signed informed consents were ob-
tained from the patients. This patient group comprised 3 unrelated pro-
bands who developed both cutaneous melanoma and intraepithelial
neoplasia of the pancreas. DNA samples were extracted from peripheral
leukocytes following standard procedures.
CDKN2A and CDK4 sequencing
DNA sequencing was conducted at the Laboratory of Genomics
and Molecular Biology (ACCCC). Direct sequencing of the CDKN2A
(p16INK4a and p14ARF) and the CDK4 genes was performed on DNA sam-
ples extracted from peripheral blood (primer sequences available upon
request). Variants of unknown clinical signiﬁcance were investigated in
dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) and 1000 Ge-
nomes (http://www.1000 genomes.org/).
DNA copy number variation (CNV) assessment
We performed the evaluation of CNVs using the CytoSNP 850K
BeadChip (Illumina) which contains 850,000 SNP probes covering the
whole-genome with enriched coverage for 3262 well-known genes of
constitutional and cancer diseases. Labeling, hybridization, andwashing
procedures followed the manufacturer's instructions. Microarray slides
were scanned using the iScan System (Illumina), and generated gtc
ﬁles were loaded on the BlueFuse Multi Software v3.2 (BlueGnome) to
evaluate experimental quality and CNV calling. Alterations had to en-
compass at least ﬁve consecutive probes with aberrant log2 values
with a minimum size of 100 kb. The detected variants were compared
to the CNVs' panel of normal populations reported in the Database of
Genomic Variants (DGV; http://projects.tcag.ca/variation/; freeze Janu-
ary 2014), and common CNVs were disregarded. Variants presenting
with frequencies b0.1% among the control individuals, and harboring
genes (thereafter referred as rare CNVs) were selected for further vali-
dation. Gene annotation was performed using the University of Califor-
nia Santa Cruz Genome Browser (UCSC; http://genome.ucsc.edu/cgi-
bin/hgGateway) and the Catalog of Somatic Mutations (COSMIC;
http://www.sanger.ac.uk/genetics/CGP/cosmic/).
Copy number validation by real-time quantitative PCR (qPCR)
In order to validate two rare CNVs, qPCR was performed using the
SYBR Green system (Applied Biosystems) on a 7500 System apparatus
(Applied Biosystems) with a reference DNA (Promega) as control for
copy number calibration. We designed probes covering coding se-
quences of one of the genes contained in each CNV (Supplementary
Table S1). Values were normalized based on data from the GAPDH
(12p13) e HPRT (Xq26.2) genes as described by Torrezan et al. (2012).
Triplicates were analyzed using the comparative 2−ΔΔCt cycle
threshold method (Livak and Schmittgen, 2001). Values in the range
of 0.8–1.2 indicated two copies, b0.6 indicated copy number loss,
and N1.4 was considered a gain.
Results
Clinical description of the three patients can be found in Table 1.
These patients were screened for point mutations affecting the coding
sequence, promoter or splice junctions of the CDKN2A gene, and no
pathogenic mutations were detected. Additionally, we investigated
the presence of CDKN2A deletions using the 850K SNP-array data, and
copy number alterations affecting the CDKN2A genomic region were
not detected.
Two rare germline CNVs validated by qPCR were detected in one of
the patients: a 616 kb duplication at 2p12 encompassing the CTNNA2
andMIR4264 genes, and a 368 kb duplication at 5q35.3 containing the
GRM6, ADAMTS2, ZNF879 and ZNF354C genes. Genomic mapping of the
variants are detailed in Table 2. These duplications occurred in genomic
segments with few or none reports in the Database of Genomic Variants
(Fig. 1).
Additionally, one patient who was 79 years-old at diagnosis was
found to exhibit loss of the entire chromosome Y in leukocytes.
Discussion
Germline copy number alterations are already known to contribute
to cancer susceptibility, including melanoma and pancreatic cancer
(Al-Sukhni et al., 2012; Krepischi et al., 2012b; Lucito et al., 2007; Silva
et al., 2012; Yang et al., 2012). A recent study identiﬁed a 4q13 germline
duplication in one melanoma family (Yang et al., 2012). Concerning
pancreatic cancer, three CNV studies provided candidate genes to
Table 1
Description of clinicopathologic features of the 3 patients regarding to melanoma and pancreatic cancer status.
Patient Rare germline
CNV
Actual
age/gender
Melanoma clinicopathologic
features (diagnostic age,
location, histopathology)
Melanoma
status disease
FMS Pancreatic cancer clinicopathologic
features (diagnostic age, symptoms,
histopathology)
Pancreatic cancer
status disease
FPCS
1 0 69 y/M 57 y, trunk, superﬁcial spreading
melanoma, B = 0.5 mm
AWD No 68 y, asymptomatic, well-differentiated
neuroendocrine tumor and IPMN
AWD No
2 Duplications at
2p12 and 5q35.3
65 y/M 58 y, trunk, superﬁcial spreading
melanoma, B = 0.45 mm, CL II
AWD No 64 y, abdominal pain, microcystic
serous cystadenoma and PanIN-1
AWD No
3 Chr. Y loss 85 y/M 78 y, trunk, lentigo maligno
melanoma, B = 3.2 mm, CL IV,
BRAF negative
Local and
linfonodal
metastatic
No 84 y, asymptomatic, invasive mucinous
adenocarcinoma and IPMN
AWD No
FMS — Familial Melanoma Syndrome; FPCS— Familial Pancreatic Cancer Syndrome; B — Breslow thickness; CL— Clarck level, PanIN-1— low grade pancreatic intraepithelial neoplasia;
IPMN — intraductal papillary mucinous carcinoma; AWD — alive without disease.
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pancreatic cancer susceptibility (Al-Sukhni et al., 2012; Huang et al.,
2012; Lucito et al., 2007).
Although loss of Y chromosome has been associated with some tu-
mors such as lymphocytic leukemia (Chapiro et al., 2014), it was already
described in lowpercentage ofmen after the seventies (Guttenbach et al.,
1995). The two detected CNVswere duplications, one of them affecting a
2p12 segment sizing 616 kb that harbors the CTNNA2 and MIR4264
genes. CTNNA2 acts at cadherin adhesion that regulates cell–cell adhesion
and differentiation (Gene Cards — www.genecards.org), and it was re-
cently described as a tumor suppressor gene in laryngeal cancer
(Fanjul-Fernández et al., 2013). Accordingly, in silico analysis using String
(http://string-db.org) puts this gene in cancer pathways. The other de-
tected rare CNV is a 5q35.3 duplication of 368 kb that harbors the
GRM6, ADAMTS2, ZNF879 and ZNF354C genes. The GRM6 gene was re-
cently seen hypermethylated in renal cell carcinomas (Arai et al.,
2012); ADAMTS2 acts as a metalloproteinase protein already reported
as altered in squamous cell carcinoma (Carinci et al., 2005). In addition,
ADAMTS2 was associated with a 2–3 fold increase of the risk for malig-
nant pleural mesothelioma development (Matullo et al., 2013).
Althoughwe cannot exclude that the occurrence of rare CNVs can be
a coincidental ﬁnding, our data on rare germline CNVs highlighted
genes that, in case of being dosage sensitive, could add to the genetic
Table 2
Description of two rare germline copy number variations (CNVs) identiﬁed in one patient, with respective genomic positions (GRCh37), ISCN 2013 description, size, type of copy number
event, and affected genes.
Cytoband Start position ISCN 2013 Size (kb) CNV type Genes affecteda
2p12 79,539,758 arr 2p12(79,539,758-80,156,246)x3 616 Duplication CTNNA2a,mir4264
5q35.3 178,413,947 arr 5q35.3(178,413,947-178,782,813)x3 368 Duplication GRM6a, ADAMTS2, ZNF879, ZNF354C
a Genes selected for validation using qPCR.
)B(A1)A(A1
1A(C)
)B(B1)A(B1
1B(C)
Fig. 1. A: Rare CNV (duplication) affecting a 616 kb genomic region at 2p12 detected by SNP-array in a melanoma/pancreatic cancer patient. (A) Probes above the baseline 0 of the Log-
Ratio representing the duplicated segment at 2p12 are highlighted in yellow. (B) Plot of the B-allele frequency exhibiting the pattern of the 2p12 duplication highlighted in yellow. (C) The
affected genomic segment at 2p12 seen by the UCSC genome browser: the region encompasses two genes, CTNNA2 andMIR4264, and the sequence used in the qPCR assay ismarked by a
red box. B: Rare CNV (duplication) affecting a 368 kbgenomic region at 5q35.3 detected by SNP-arrays in amelanoma/pancreatic cancer patient. (A) Probes above the baseline 0 of the Log-
Ratio representing the 5q35.3 duplication highlighted in yellow. (B) Plot of the B-allele frequency presenting a pattern of the 5q35.3 duplication highlighted in yellow. (C) The affected
genomic segment at 5q35.3 seen by the UCSC genome browser: the region encompasses four genes, GRM6, ADAMTS2, ZNF879 and ZNF354C, and the sequence used in the qPCR assay is
marked by a red box.
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basis of the cancer predisposition of melanoma associated with a pan-
creatic neoplasia.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yexmp.2014.06.013.
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